


# Levodopa Market Update 2024: to Reach USD 2.9 billion by 2032, Claims AMR Report

The increasing prevalence of Parkinson's disease, rising healthcare expenditure & technological advancements in drug delivery are projected to drive the market

PORTLAND, OREGON, UNITED STATES, April 29, 2024 /EINPresswire.com/ --Allied Market Research has recently published a report, titled, "<u>Levodopa</u> <u>Market</u> Size, Share, Competitive



Landscape and Trend Analysis Report by Form, by Route of Administration, by Distribution Channels: Global Opportunity Analysis and Industry Forecast, 2023-2032." According to the report, the global levodopa market generated \$1.7 billion in 2022, and is anticipated to generate \$2.9 billion by 2032, rising at a CAGR of 6.1% from 2023 to 2032.

The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.

### $000\ 00000000\ 000000\ 0000000$

- UCB SA
- Mylan Nv
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Bristol-Myers Squibb Co.
- Sun Pharmaceutical Industries Ltd.
- · Pfizer Inc.
- Merck and Co. Inc.
- Impax Laboratories Inc.
- Novartis AG

# 

# 

The growing prevalence of Parkinson's disease, the increasing demand for therapeutic Interventions, and the increasing healthcare expenditure are the factors expected to drive the growth of the global levodopa market in the forecast period from 2023 to 2032. However, the side effects and safety concerns associated with the levodopa may hamper the market growth in the coming future. On the contrary, the development of novel formulations and efficient drug delivery methods and technological advancements in drug delivery are expected to offer remunerative opportunities for the expansion of the levodopa market during the forecast period.

# 

The tablets sub-segment accounted for the largest global levodopa market share of 36.0% in 2022 and is expected to grow at the highest CAGR of 7.0% during the forecast period. Levodopa tablets are favored for their convenience, affordability, and widespread adoption among patients. Offering a simple and familiar mode of administration, tablets enhance patient adherence to treatment routines. Moreover, the availability of various tablet strengths allows for flexible dosing tailored to individual patient needs, optimizing therapeutic outcomes. Additionally, tablets are relatively cost-effective compared to alternative formulations, ensuring accessibility to a broader patient population.

The oral sub-segment accounted for the largest market share of 57.7% in 2022 and dominate in terms of market share by 2032. This dominance is majorly owing to the convenience, familiarity, and widespread adoption of oral administration among patients and healthcare providers. With various dosages available, patients can easily adhere to treatment regimens. Additionally, the accessibility and versatility of the oral route make it a preferred choice, especially in early to midstage Parkinson's disease.

The retail pharmacies sub-segment accounted for the largest market share of 34.1% in 2022 and is predicted to witness prominent growth by 2032. This is majorly because the widespread accessibility of retail pharmacies provides convenient access to levodopa for patients managing Parkinson's disease. Additionally, the presence of trained pharmacists in retail settings offers personalized guidance and support to patients, enhancing treatment adherence and satisfaction. Furthermore, retail pharmacies often stock a variety of medications, including levodopa, allowing patients to fulfill their prescriptions conveniently.

The levodopa market in the North America region accounted for the largest share of 40.9% in 2022 and is predicted to continue to maintain its dominance in terms of market share during the forecast period. The robust healthcare infrastructure and advanced medical research facilities in

North America foster innovation in Parkinson's disease management. This environment encourages the development of novel levodopa formulations and treatment approaches, driving market growth. Besides, the region's high prevalence of Parkinson's disease, combined with an aging population, and supportive healthcare policies contributes to the growth of the levodopa market in North America.

# Key Benefits For Stakeholders

- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the Levodopa Market analysis from 2021 to 2031 to identify the prevailing Levodopa Market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the Levodopa Market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global Levodopa Market size.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global Levodopa Market trends, key players, market segments, application areas, and market growth strategies.

## 

- Which are the driving factors responsible for the growth of market?
- Which are the roadblock factors of this market?
- What are the new opportunities, by which market will grow in coming years?
- What are the trends of this market?
- Which are main factors responsible for new product launch?
- How big is the global & regional market in terms of revenue, sales and production?
- How far will the market grow in forecast period in terms of revenue, sales and production?
- Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
- How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
- Which region has more opportunities?

- North America
   (U.S., Canada, Mexico)
- Europe

(Germany, France, UK, Italy, Spain, Rest of Europe)

Asia-Pacific

(Japan, China, India, Rest of Asia-Pacific)

LAMEA

(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

### 0000000 0000000:

David Correa USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022 help@alliedmarketresearch.com

### 0000000

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa
Allied Market Research
+1 503-894-6022
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Other

This press release can be viewed online at: https://www.einpresswire.com/article/707310225

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.